Clinical Trial Update: Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 [Phase 1]

View source ↗

Summary

Braeburn Pharmaceuticals reports the completed Phase 1 study evaluating D2 receptor occupancy after a single intravenous dose of ATI-9242 in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ATI-9242

Snippet

Sponsor: Braeburn Pharmaceuticals | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED